

08-17-05

1647

PTO/SB/21 (09-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

13

Application Number

09/322,289

Filing Date

May 28, 1999

First Named Inventor

Schenk, Dale B.

Art Unit


1647

Examiner Name

Sharon L. Turner

Attorney Docket Number

15270J-004740US

**ENCLOSURES (Check all that apply)**

- |  |   |   |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form   | <input type="checkbox"/> Drawing(s)   | <input type="checkbox"/> After Allowance Communication to TC                            |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Licensing-related Papers   | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply   | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition to Convert to a Provisional Application                               | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)   | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address                 | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request   | <input type="checkbox"/> Terminal Disclaimer  | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):         |
| <input type="checkbox"/> Express Abandonment Request   | <input type="checkbox"/> Request for Refund   | Return postcard   |
| <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (6 pgs.) PTO/SB/08A (1 pg.) PTO/SB/08B (3 pgs.); * copies of cited references 580 and 585-626. | <input type="checkbox"/> CD, Number of CD(s) _____  |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)  | <input type="checkbox"/> Landscape Table on CD  |   |
| <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application  | <b>Remarks</b> The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. |   |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53  | * Not included in "Total Number of Pages In This Submission"  |   |

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Neil G. Miyamoto		
Date	August 15, 2005	Reg. No.	50,370

**CERTIFICATE OF TRANSMISSION/MAILING**

Express Mail Label: EV 732 173 545 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date August 15, 2005 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature

Typed or printed name

Jordan Magat

Date

August 15, 2005



Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

**FEE TRANSMITTAL**  
For FY 2005☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 180.00)**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Examiner Name	Turner, S. L.
Art Unit	1647
Attorney Docket No.	15270J-004740US

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Small Entity	Small Entity	Small Entity	Small Entity	Small Entity	
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

<b>Total Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	<b>Multiple Dependent Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
_____	_____	_____	_____	_____	_____	_____

HP = highest number of total claims paid for, if greater than 20

<b>Indep. Claims</b>	<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
_____	_____	_____	_____

HP = highest number of independent claims paid for, if greater than 3

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
_____	_____	_____	_____	_____

\_\_\_\_\_ - 100 = \_\_\_\_\_ / 50 = \_\_\_\_\_ (round up to a whole number) x \_\_\_\_\_ = \_\_\_\_\_

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement (after office action)

**Fees Paid (\$)**

180.00

**SUBMITTED BY**


Signature		Registration No. (Attorney/Agent) 50,370	Telephone (650) 326-2400
Name (Print/Type)	Neil G. Miyamoto		Date August 15, 2005

"Express Mail" Label No. EV 732 173 545 US

Date of Deposit: August 15, 2005

PATENT  
Attorney Docket No.: 15270J-004740US  
Client Reference No.: 209-US-CIP5

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:



Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: Jordan Magat  
Jordan Magat

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references 580 and 585-626 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;

08/18/2005 EFLORES 00000004 201430 09322289

01 FC:1806 180.00 DA

09/497,553 filed 02/03/00;  
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;  
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;  
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;  
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;  
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;  
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;  
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;  
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;  
10/934,818 filed 09/02/04;  
10/934,609 filed 09/02/04 issue fee paid 01/24/05;  
10/933,559 filed 09/02/04 issue fee paid 01/24/05;  
10/934,819 filed 09/02/04;  
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;  
10/816,380 filed 03/31/04 issue fee paid 01/24/05;  
10/815,404 filed 03/31/04 issue fee paid 11/12/04;  
09/322,289 filed 05/28/99;  
09/723,713 filed 11/27/00;  
09/723,760 filed 11/27/00;  
09/724,319 filed 11/27/00;  
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;  
09/724,495 filed 11/27/00;  
10/788,666 filed 02/27/04;  
10/429,216 filed 05/30/03;  
10/828,548 filed 04/19/04;  
10/923,471 filed 08/20/04;  
10/923,474 filed 08/20/04;  
10/928,926 filed 08/27/04;  
10/923,605 filed 08/20/04;  
10/923,267 filed 08/20/04;

10/923,469 filed 08/20/04;  
09/580,015 filed 05/26/00;  
09/724,940 filed 11/28/00 issue fee paid 11/12/04;  
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;  
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;  
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;  
09/723,544 filed 11/28/00;  
09/724,273 filed 11/28/00;  
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;  
09/724,288 filed 11/28/00;  
10/777,792 filed 02/11/04;  
10/890,024 filed 04/12/04;  
10/889,999 filed 04/12/04;  
10/890,000 filed 07/12/04;  
10/890,070 filed 07/12/04;  
10/890,071 filed 07/12/04;  
09/580,019 filed 05/26/00;  
09/723,765 filed 11/28/00;  
09/724,291 filed 11/28/00;  
10/822,968 filed 04/12/04;  
09/724,929 filed 11/28/00;  
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;  
09/724,575 filed 11/28/00;  
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;  
09/724,570 filed 11/28/00 issue fee paid 02/10/05;  
09/585,656 filed 06/01/00;  
09/723,766 filed 11/27/00;  
09/723,725 filed 11/27/00;  
09/579,690 filed 05/26/00;  
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);  
issued as U.S. 6,913,745 on 07/05/05; and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related  
subject matter but subject to different assignment:

10/010,942 filed 12/06/01;

10/789,273 filed 02/27/04;

10/232,030 filed 08/30/02;

10/010,942 filed 12/06/01;

10/388,389 filed 03/12/03;

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04.

60/622,525 filed 10/26/04;

60/636,684 filed 12/15/04;

60/636,842 filed 12/15/04;

60/637,253 filed 12/16/04;

60/636,810 filed 12/15/04;

60/637,138 filed 12/16/04;

60/636,776 filed 12/15/04;

60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications  
directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00;  
09/724,929 filed 11/28/00;  
60/137,010 filed 06/01/99;  
60/251,892 filed 12/06/00;  
60/137,047 filed 06/01/99;  
60/136,655 filed 05/28/99; and  
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;  
60/474,654 filed 05/30/03;  
60/530,481 filed 12/17/03;  
60/444,150 filed 02/01/03; and,  
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;  
09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00; and,  
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Neil G. Miyamoto  
Reg. No. 50,370

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:crf





\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Turner, Sharon L.
Sheet	2	of	4	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <u>Neuroscience Letters</u> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <u>The Scientist</u> , 18(20):28-29 (2004).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- $\beta$ in vivo by immunotherapy," <u>J. Neurosci.</u> , 22(18):7873-7878 (2002).	
	591	CHROMY et al., "Self-assembly of A $\beta$ (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- $\beta$ protein are generated from the $\beta$ -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002).	
	594	DEMATTOIS et al., "Brain to plasma amyloid- $\beta$ efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A $\beta$ burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	
	598	DUFF et al., "Increased amyloid- $\beta$ 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target $\gamma$ -secretase and lower A $\beta$ 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid $\beta$ -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
	601	FRENKEL et al., "Reduction of $\beta$ -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Turner, Sharon L.
Sheet	3	of	4	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	602	FRENKEL et al., "Towards Alzheimer's $\beta$ -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A $\beta$ ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	
	607	HOCK et al., "Generation of antibodies specific for $\beta$ -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- $\beta$ peptide target amyloid- $\beta$ residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid $\beta$ protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the $\gamma$ -secretase sites is not cleaved to $\beta$ -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of $\beta$ -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A $\beta$ immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Turner, Sharon L.
Sheet	4	of	4	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
	619	SIGURDSSON et al., "Immunization with a nontoxic/nonfibrillar amyloid- $\beta$ homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice," <u>Am. J. Pathol.</u> , 159(2):439-447 (2001).	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against $\beta$ -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid $\beta$ protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	
	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.